# Flunitrazepam
*Source: https://go.drugbank.com/drugs/DB01544*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

### Background

Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.

### Indication

For short-term treatment of severe insomnias, that are not responsive to other hypnotics.

### Pharmacodynamics

Flunitrazepam is a powerful hypnotic drug that is a benzodiazepine derivative. It has powerful hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties. The drug is sometimes used as a date rape drug. In the United States, the drug has not been approved by the Food and Drug Administration for medical use, and is considered to be an illegal drug. It has however been approved in the United Kingdom and other countries.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Absorption

50% (suppository) and 64-77% (oral)

### Metabolism

Hepatic.

### Half-life

18-26 hours

### Toxicity

Symptoms of overdose include confusion, coma, impaired coordination, sleepiness, and slowed reaction time.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Flunitrazepam is combined with 1,2-Benzodiazepine.
Abacavir
The metabolism of Abacavir can be decreased when combined with Flunitrazepam.
Abametapir
The serum concentration of Flunitrazepam can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Flunitrazepam can be increased when combined with Abatacept.
Abrocitinib
The metabolism of Abrocitinib can be decreased when combined with Flunitrazepam.

### Food Interactions

Avoid alcohol.
Avoid grapefruit products.
Limit caffeine intake.
Take with food.

## Chemical Information

**DrugBank ID:** DB01544

**Synonyms:** Flunitrazepam
Flunitrazepamum

**Chemical Formula:** C
16
H
12
FN
3
O
3

**SMILES:** CN1C2=C(C=C(C=C2)[N+]([O-])=O)C(=NCC1=O)C1=CC=CC=C1F

**Weight:** Average: 313.2832
Monoisotopic: 313.08626947

**IUPAC Name:** 5-(2-fluorophenyl)-1-methyl-7-nitro-2,3-dihydro-1H-1,4-benzodiazepin-2-one

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

2

### Phase 0

0

### Phase 1

0

### Phase 2

0

### Phase 3

0

### Phase 4

0

### Summary

Flunitrazepam
is a benzodiazepine used to manage anxiety disorders and insomnia.

### Generic Name

Flunitrazepam

### DrugBank Accession Number

DB01544

### Groups

Approved, Illicit

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Flunitrazepam (DB01544)
×
Close

### External IDs

RO 5-4200
RO-5-4200
RO-54200

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Treatment of
Anxiety
••••••••••••
Create Account
••••••• •••• ••••••
Treatment of
Insomnia
••••••••••••
Create Account
••••••• •••• ••••••
Create Account

### Mechanism of action

Benzodiazepines bind nonspecifically to benzodiazepine receptors BNZ1, which mediates sleep, and BNZ2, which affects affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of the inhibitory neurotransmitter GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans
U
Translocator protein
agonist
Humans

### International/Other Brands

Hipnosedon (Roche)
/
Hypnodorm (Alphapharm)
/
Narcozep (Roche)
/
Rohypnol (Roche)
/
Roipnol (Roche)

### ATC Codes

N05CD03 — Flunitrazepam
N05CD — Benzodiazepine derivatives
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anti-Anxiety Agents
Benzazepines
Benzodiazepine hypnotics and sedatives
Benzodiazepines and benzodiazepine derivatives
Benzodiazepinones
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP2A6 Substrates
Cytochrome P-450 CYP2B6 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2E1 Inhibitors
Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
Cytochrome P-450 CYP3A Substrates
Cytochrome P-450 CYP3A4 Substrates
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Hypnotics and Sedatives
Muscle Relaxants
Muscle Relaxants, Centrally Acting Agents
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents
UGT1A1 Inhibitors
UGT1A3 Inhibitors
UGT2B7 Inhibitors

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives
/
Nitroaromatic compounds
/
Fluorobenzenes
/
Aryl fluorides
/
Tertiary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Organic oxoazanium compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organofluorides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more
Substituents
1,4-benzodiazepine
/
Allyl-type 1,3-dipolar organic compound
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl fluoride
/
Aryl halide
/
Azacycle
/
Benzenoid
/
C-nitro compound
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Fluorobenzene
/
Halobenzene
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Monocyclic benzene moiety
/
Nitroaromatic compound
/
Organic 1,3-dipolar compound
/
Organic nitro compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxoazanium
/
Organic oxygen compound
/
Organofluoride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Tertiary carboxylic acid amide
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,4-benzodiazepines

### Alternative Parents

Alpha amino acids and derivatives
/
Nitroaromatic compounds
/
Fluorobenzenes
/
Aryl fluorides
/
Tertiary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Organic oxoazanium compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organofluorides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more

### Substituents

1,4-benzodiazepine
/
Allyl-type 1,3-dipolar organic compound
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl fluoride
/
Aryl halide
/
Azacycle
/
Benzenoid
/
C-nitro compound
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Fluorobenzene
/
Halobenzene
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Monocyclic benzene moiety
/
Nitroaromatic compound
/
Organic 1,3-dipolar compound
/
Organic nitro compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxoazanium
/
Organic oxygen compound
/
Organofluoride
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Tertiary carboxylic acid amide
show 23 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### Affected organisms

Humans and other mammals

### UNII

620X0222FQ

### CAS number

1622-62-4

### InChI Key

PPTYJKAXVCCBDU-UHFFFAOYSA-N

### InChI

InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3

### Synthesis Reference

Kariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.  Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc.  Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.

### General References

Rickels K: The clinical use of hypnotics: indications for use and the need for a variety of hypnotics. Acta Psychiatr Scand Suppl. 1986;332:132-41. [
Article
]
Robertson MD, Drummer OH: Postmortem drug metabolism by bacteria. J Forensic Sci. 1995 May;40(3):382-6. [
Article
]
Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [
Article
]
Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A: Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5. [
Article
]
Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. [
Article
]

### External Links

Human Metabolome Database
HMDB0015510
KEGG Drug
D01230
PubChem Compound
3380
PubChem Substance
46504553
ChemSpider
3263
BindingDB
25878
RxNav
4460
ChEBI
31622
ChEMBL
CHEMBL13280
ZINC
ZINC000003812994
Therapeutic Targets Database
DAP000931
PharmGKB
PA164781320
Wikipedia
Flunitrazepam

### Human Metabolome Database

HMDB0015510

### KEGG Drug

D01230

### PubChem Compound

3380

### PubChem Substance

46504553

### ChemSpider

3263

### BindingDB

25878

### RxNav

4460

### ChEBI

31622

### ChEMBL

CHEMBL13280

### ZINC

ZINC000003812994

### Therapeutic Targets Database

DAP000931

### PharmGKB

PA164781320

### Wikipedia

Flunitrazepam

### Dosage Forms

Form
Route
Strength
Capsule
Oral
2 MG
Solution / drops
0.2 %
Tablet, film coated
Oral
1 mg
Tablet, film coated
Oral
Tablet
Oral
2 MG
Tablet
Oral
1 MG

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
166-167 °C
Kariss, J. and Newmark, H.L.; U.S. Patent 3,116,203; December 31, 1963; assigned to Hoffmann-la Roche Inc.  Kariss, J. and Newmark, H.L.; US. Patent 3,123,529; March 3,1964; assigned to Hoffmann-La Roche Inc.  Keiler, O., Steiger, N. and Sternbach, L.H.; U.S. Patent 3,203,990; August 31, 1965; assigned to Hoffmann-La Roche Inc.
logP
2.06
HANSCH,C ET AL. (1995)

### Predicted Properties

Property
Value
Source
Water Solubility
0.00858 mg/mL
ALOGPS
logP
2.2
ALOGPS
logP
2.55
Chemaxon
logS
-4.6
ALOGPS
pKa (Strongest Basic)
1.72
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
4
Chemaxon
Hydrogen Donor Count
0
Chemaxon
Polar Surface Area
75.81 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
81.54 m
3
·mol
-1
Chemaxon
Polarizability
29.67 Å
3
Chemaxon
Number of Rings
3
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9922
Blood Brain Barrier
+
0.973
Caco-2 permeable
+
0.5257
P-glycoprotein substrate
Substrate
0.6717
P-glycoprotein inhibitor I
Non-inhibitor
0.6428
P-glycoprotein inhibitor II
Non-inhibitor
0.9094
Renal organic cation transporter
Non-inhibitor
0.713
CYP450 2C9 substrate
Non-substrate
0.7621
CYP450 2D6 substrate
Non-substrate
0.8932
CYP450 3A4 substrate
Substrate
0.725
CYP450 1A2 substrate
Non-inhibitor
0.5691
CYP450 2C9 inhibitor
Non-inhibitor
0.5163
CYP450 2D6 inhibitor
Non-inhibitor
0.8776
CYP450 2C19 inhibitor
Inhibitor
0.5957
CYP450 3A4 inhibitor
Inhibitor
0.5626
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.5555
Ames test
AMES toxic
0.9108
Carcinogenicity
Non-carcinogens
0.7209
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
2.8125 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9869
hERG inhibition (predictor II)
Non-inhibitor
0.8074
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-03du-2191000000-6d65c6a7646264996d7c
Mass Spectrum (Electron Ionization)
MS
splash10-01p9-2393000000-5d873203e4acf1211838
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-03di-0009000000-d3cdbd0e6db0ff7d3658
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-02t9-0098000000-ed4fc29ca5e103e7e7ac
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-014i-0292000000-910e58767edf9829ae76
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-000i-0590000000-f32a6119c0a1af4b09f1
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-03di-0009000000-0917b69ebd96bce7d228
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-03di-0009000000-52198b26a21902b1164d
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-02t9-0095000000-6905e6ef41a999c5c6bb
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014r-0291000000-05daa60855227774f98a
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-01p9-0590000000-1dc724d4ffca2a0dcc87
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0230-0970000000-c801330e64d95e44fce8
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-00si-1920000000-6d855cf670784a504122
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-001i-2910000000-ab0a5646c93755d78538
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0gx0-3900000000-0e0998c190e076f40d1b
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
181.1967766
predicted
DarkChem Lite v0.1.0
[M-H]-
164.86116
predicted
DeepCCS 1.0 (2019)
[M+H]+
181.6544766
predicted
DarkChem Lite v0.1.0
[M+H]+
167.2192
predicted
DeepCCS 1.0 (2019)
[M+Na]+
181.3780766
predicted
DarkChem Lite v0.1.0
[M+Na]+
173.90341
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Substrate

### Curator comments

Benzodiazepines modulate GABA(A) function by binding at the interface between alpha (α) and gamma (γ) subunits. Of the 6 α-subunits, only 4 (α-1, -2, -3, and -5) participate in the formation of this binding site. The above target is a collection of all α- and γ-subunits that are known to participate in the formation of the benzodiazepine binding site.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:18577768, PubMed:19965576, PubMed:20972997). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates PUFA specifically at the omega-1 position (PubMed:18577768). Catalyzes the epoxidation of double bonds of PUFA (PubMed:19965576, PubMed:20972997). Also metabolizes plant monoterpenes such as limonene. Oxygenates (R)- and (S)-limonene to produce carveol and perillyl alcohol (PubMed:11950794). Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine. Hydroxylates fenbendazole at the 4' position (PubMed:23959307)

### Specific Function

(R)-limonene 6-monooxygenase activity

### Gene Name

CYP2C19

### Uniprot ID

P33261

### Uniprot Name

Cytochrome P450 2C19

### Molecular Weight

55944.565 Da

